OncoMatch/Clinical Trials/NCT04706910

18F-DOPA II - PET Imaging Optimization

Is NCT04706910 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including 18F-DOPA and Furosemide for congenital hyperinsulinism.

Treatment: 18F-DOPA · Furosemide — A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism. 2. Pediatric patients (less than 18 years old) with neuroblastoma. 3. Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor. 4. Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia. 5. Pediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors. Image optimization (the primary study objective) and gallbladder activity pattern (the secondary objective) will be evaluated.